Used in low doses, methylene blue is proposed to support memory, mental clarity, and mitochondrial brain function. It may boost cytochrome oxidase activity, reduce oxidative stress, and help inhibit amyloid/toxic protein buildup—making it of interest for early Alzheimer’s or Parkinson’s support. Most of this evidence comes from animal studies or very limited human trials.

We also use methylene blue to support cellular energy metabolism—especially in conditions like chronic fatigue, fibromyalgia, or long COVID—due to its role as an electron carrier improving mitochondrial efficiency and ATP production.

Methylene blue is gaining interest in integrative oncology as an adjunctive therapy due to its unique ability to support mitochondrial function, enhance oxidative stress selectively in cancer cells, and serve as a photosensitizer in photodynamic therapy (PDT). When activated by specific wavelengths of light, methylene blue can generate reactive oxygen species that damage tumor cells while sparing healthy tissue. It may also sensitize cancer cells to chemotherapy or radiation by disrupting their redox balance and impairing drug resistance mechanisms. While not FDA-approved for cancer treatment, it’s being explored in experimental protocols for cancers such as breast, oral, and bladder, and is occasionally used in surgical settings to delineate tumor margins.